22UA:FRA
BioNTech SE - ADR
€78.05
arrow_downward
-0.06%(-0.050) 1D
Oct 19, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€78.05
High
€78.75
Low
€77.90
Mkt. cap
22.41B
Avg. vol.
1.42K
Volume
151.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
Open
€78.05
High
€78.75
Low
€77.90
Mkt. cap
22.41B
Avg. vol.
1.42K
Volume
151.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
News stories
From web sources and news partners
Stock Titan
·
9 hours ago
BioNTech will share first data on a drug combination for advanced lung cancer
The Motley Fool
·
1 day ago
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Yahoo Finance
·
2 days ago
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR